ARTICLE | Product Development
Action needed to prevent manufacturing bottlenecks on COVID-19 therapies
Urgent steps needed to prioritize, expand manufacturing capacity for most promising therapies
June 24, 2020 1:33 AM UTC
Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars.
A survey of BIO members conducted by the Boston Consulting Group (BCG) has identified bottlenecks that, if not addressed quickly, could limit supplies of drugs, and in particular biologics, to treat COVID-19. ...